Overview

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophy

Status:
Completed
Trial end date:
2017-04-18
Target enrollment:
Participant gender:
Summary
ATYR1940-C-006 is a multi-national, multicenter study being conducted at centers in the United States (US) and Europe who participated in the Study ATYR1940-C-003 (Stage 1 only) or ATYR1940-C-004 (i.e., the parent studies).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
aTyr Pharma, Inc.